Review

antibodies targeting adam17 (Bioss)

Bioss is a verified supplier

Bioss manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bioss antibodies targeting adam17

(A) Gene expression of <t>ADAM17</t> in lung tissue three hours after LPS inhalation, measured by RT-qPCR (n = 4/4/14/8 mice per group). Expression data were normalized to the ADAM17 fl/fl Tie2-Cre − LPS control group, whose mean value was set to 1. (B) Quantification of ADAM17 mean fluorescence intensity (MFI) in lung tissue using LasX software (n = 4 mice per group; 10 measurements per image). (C) Representative z-stack immunofluorescence images showing ADAM17 expression in lung tissue under the indicated conditions (original magnification ×63). Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA with appropriate post hoc testing; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Antibodies Targeting Adam17, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+adam17+antibody/bio_rxiv__64898__2026__01__21__700786-29-6-12?v=Bioss
Average 91 stars, based on 2 article reviews

antibodies targeting adam17 - by Bioz Stars, 2026-08

91/100 stars

Images

1) Product Images from "Endothelial ADAM17 Promotes Neutrophil Migration and Pulmonary Microvascular Permeability in ARDS"

Article Title: Endothelial ADAM17 Promotes Neutrophil Migration and Pulmonary Microvascular Permeability in ARDS

Journal: bioRxiv

doi: 10.64898/2026.01.21.700786

(A) Gene expression of ADAM17 in lung tissue three hours after LPS inhalation, measured by RT-qPCR (n = 4/4/14/8 mice per group). Expression data were normalized to the ADAM17 fl/fl Tie2-Cre − LPS control group, whose mean value was set to 1. (B) Quantification of ADAM17 mean fluorescence intensity (MFI) in lung tissue using LasX software (n = 4 mice per group; 10 measurements per image). (C) Representative z-stack immunofluorescence images showing ADAM17 expression in lung tissue under the indicated conditions (original magnification ×63). Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA with appropriate post hoc testing; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Figure Legend Snippet: (A) Gene expression of ADAM17 in lung tissue three hours after LPS inhalation, measured by RT-qPCR (n = 4/4/14/8 mice per group). Expression data were normalized to the ADAM17 fl/fl Tie2-Cre − LPS control group, whose mean value was set to 1. (B) Quantification of ADAM17 mean fluorescence intensity (MFI) in lung tissue using LasX software (n = 4 mice per group; 10 measurements per image). (C) Representative z-stack immunofluorescence images showing ADAM17 expression in lung tissue under the indicated conditions (original magnification ×63). Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA with appropriate post hoc testing; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Techniques Used: Gene Expression, Quantitative RT-PCR, Expressing, Control, Fluorescence, Software, Immunofluorescence

Endothelial ADAM17 enhances neutrophil migration into the inflamed lung. (A–D) Representative immunohistochemical images showing polymorphonuclear neutrophil (PMN) distribution in lung tissue under the indicated conditions. PMNs were stained using an anti-Ly6G+C antibody (brown) with hematoxylin counterstain. Red arrows indicate PMNs (n = 4 mice per group; original magnification ×20). (E) Quantification of PMNs per high-power field (HPF; n = 4 mice per group, 10 images per group). (F–I) Flow cytometric quantification of PMNs in blood (F), adherent to the pulmonary endothelium (G), within the interstitium (H), and in BAL fluid (I) 24 hours after LPS inhalation (n = 4/4/12–14/8). (J–L) Quantification of CD162 (PSGL-1) MFI and (M–O) CD49d MFI on PMNs isolated from blood, lung, and BAL Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA.

Figure Legend Snippet: Endothelial ADAM17 enhances neutrophil migration into the inflamed lung. (A–D) Representative immunohistochemical images showing polymorphonuclear neutrophil (PMN) distribution in lung tissue under the indicated conditions. PMNs were stained using an anti-Ly6G+C antibody (brown) with hematoxylin counterstain. Red arrows indicate PMNs (n = 4 mice per group; original magnification ×20). (E) Quantification of PMNs per high-power field (HPF; n = 4 mice per group, 10 images per group). (F–I) Flow cytometric quantification of PMNs in blood (F), adherent to the pulmonary endothelium (G), within the interstitium (H), and in BAL fluid (I) 24 hours after LPS inhalation (n = 4/4/12–14/8). (J–L) Quantification of CD162 (PSGL-1) MFI and (M–O) CD49d MFI on PMNs isolated from blood, lung, and BAL Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA.

Techniques Used: Migration, Immunohistochemical staining, Staining, Isolation

(A) Schematic overview of ADAM17 maturation and intracellular transport. (B–D) Schematic representations of TNFR1/2 (B) , IL-6R (C) , and TLR4 (D) signaling pathways. (E) RT-qPCR-based gene expression analysis of inflammatory signaling components in murine lung tissue three hours after LPS inhalation (n = 4/4/10–14/6–8). (F–G) Quantification of TNFR1 (F) and IL-6Rα (G) MFI in lung tissue using LasX (n = 4 mice per group; 10 measurements per image). Data are presented as mean ± SD; Statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA.

Figure Legend Snippet: (A) Schematic overview of ADAM17 maturation and intracellular transport. (B–D) Schematic representations of TNFR1/2 (B) , IL-6R (C) , and TLR4 (D) signaling pathways. (E) RT-qPCR-based gene expression analysis of inflammatory signaling components in murine lung tissue three hours after LPS inhalation (n = 4/4/10–14/6–8). (F–G) Quantification of TNFR1 (F) and IL-6Rα (G) MFI in lung tissue using LasX (n = 4 mice per group; 10 measurements per image). Data are presented as mean ± SD; Statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA.

Techniques Used: Protein-Protein interactions, Quantitative RT-PCR, Gene Expression

Flow cytometric analysis of PMN distribution across lung compartments—blood (A) , endothelial-adherent (B) , interstitial (C) , and BAL (D) -24 hours after LPS inhalation with or without systemic ADAM17 inhibition (n = 4/13–14/7/7). (E) Quantification of CXCL2/3 in BAL fluid three hours after LPS inhalation by ELISA (n = 4/12/7/7). (F) Quantification of JAM-A MFI on pulmonary endothelial cells 24 hours after LPS inhalation (n = 4/14/7/7). (G) Quantification of VE-cadherin MFI in lung tissue using LasX (n = 4 mice per group; 10 measurements per image). (H–I) Photometric quantification of Evans blue in plasma (H) and lung tissue (I) six hours after LPS inhalation (n = 4/11/7/6–7). The data shown for ADAM17 fl/fl Tie2-Cre - controls were previously presented in the following panels: in , in , in , and in (to minimize animal numbers in accordance with the 3R principle). Data are presented as mean ± SD; Statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA.

Figure Legend Snippet: Flow cytometric analysis of PMN distribution across lung compartments—blood (A) , endothelial-adherent (B) , interstitial (C) , and BAL (D) -24 hours after LPS inhalation with or without systemic ADAM17 inhibition (n = 4/13–14/7/7). (E) Quantification of CXCL2/3 in BAL fluid three hours after LPS inhalation by ELISA (n = 4/12/7/7). (F) Quantification of JAM-A MFI on pulmonary endothelial cells 24 hours after LPS inhalation (n = 4/14/7/7). (G) Quantification of VE-cadherin MFI in lung tissue using LasX (n = 4 mice per group; 10 measurements per image). (H–I) Photometric quantification of Evans blue in plasma (H) and lung tissue (I) six hours after LPS inhalation (n = 4/11/7/6–7). The data shown for ADAM17 fl/fl Tie2-Cre - controls were previously presented in the following panels: in , in , in , and in (to minimize animal numbers in accordance with the 3R principle). Data are presented as mean ± SD; Statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA.

Techniques Used: Inhibition, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

Image Search Results

Journal: bioRxiv

Article Title: Endothelial ADAM17 Promotes Neutrophil Migration and Pulmonary Microvascular Permeability in ARDS

doi: 10.64898/2026.01.21.700786

Figure Lengend Snippet: (A) Gene expression of ADAM17 in lung tissue three hours after LPS inhalation, measured by RT-qPCR (n = 4/4/14/8 mice per group). Expression data were normalized to the ADAM17 fl/fl Tie2-Cre − LPS control group, whose mean value was set to 1. (B) Quantification of ADAM17 mean fluorescence intensity (MFI) in lung tissue using LasX software (n = 4 mice per group; 10 measurements per image). (C) Representative z-stack immunofluorescence images showing ADAM17 expression in lung tissue under the indicated conditions (original magnification ×63). Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA with appropriate post hoc testing; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: Sections were then incubated with primary antibodies targeting ADAM17 (rabbit anti-ADAM17, polyclonal, Bioss, USA), Ly6G/C (rat anti-Ly6G/C, clone RB6-8C5, Abcam, UK), VE-Cadherin (goat anti-VE-Cadherin, polyclonal, R&D Systems, USA), TNFR1 (mouse anti-TNFR1, clone H-5, Santa Cruz, USA), IL-6Rα (mouse anti-IL-6Rα, clone H-7, Santa Cruz, USA), and vWF (sheep anti-vWF, polyclonal, Abcam, UK) followed by incubation with the corresponding fluorescently labelled secondary antibodies including Alexa Fluor 488 goat anti-rabbit, Alexa Fluor 647 goat anti-rat, Alexa Fluor 488 donkey anti-goat, Alexa Fluor 594 goat anti-mouse, Alexa Fluor 488 donkey anti-mouse and Alexa Fluor 647 donkey anti-sheep.

Techniques: Gene Expression, Quantitative RT-PCR, Expressing, Control, Fluorescence, Software, Immunofluorescence

Journal: bioRxiv

Article Title: Endothelial ADAM17 Promotes Neutrophil Migration and Pulmonary Microvascular Permeability in ARDS

doi: 10.64898/2026.01.21.700786

Figure Lengend Snippet: Endothelial ADAM17 enhances neutrophil migration into the inflamed lung. (A–D) Representative immunohistochemical images showing polymorphonuclear neutrophil (PMN) distribution in lung tissue under the indicated conditions. PMNs were stained using an anti-Ly6G+C antibody (brown) with hematoxylin counterstain. Red arrows indicate PMNs (n = 4 mice per group; original magnification ×20). (E) Quantification of PMNs per high-power field (HPF; n = 4 mice per group, 10 images per group). (F–I) Flow cytometric quantification of PMNs in blood (F), adherent to the pulmonary endothelium (G), within the interstitium (H), and in BAL fluid (I) 24 hours after LPS inhalation (n = 4/4/12–14/8). (J–L) Quantification of CD162 (PSGL-1) MFI and (M–O) CD49d MFI on PMNs isolated from blood, lung, and BAL Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA.

Techniques: Migration, Immunohistochemical staining, Staining, Isolation

Journal: bioRxiv

Article Title: Endothelial ADAM17 Promotes Neutrophil Migration and Pulmonary Microvascular Permeability in ARDS

doi: 10.64898/2026.01.21.700786

Figure Lengend Snippet: (A) Schematic overview of ADAM17 maturation and intracellular transport. (B–D) Schematic representations of TNFR1/2 (B) , IL-6R (C) , and TLR4 (D) signaling pathways. (E) RT-qPCR-based gene expression analysis of inflammatory signaling components in murine lung tissue three hours after LPS inhalation (n = 4/4/10–14/6–8). (F–G) Quantification of TNFR1 (F) and IL-6Rα (G) MFI in lung tissue using LasX (n = 4 mice per group; 10 measurements per image). Data are presented as mean ± SD; Statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA.

Techniques: Protein-Protein interactions, Quantitative RT-PCR, Gene Expression

Journal: bioRxiv

Article Title: Endothelial ADAM17 Promotes Neutrophil Migration and Pulmonary Microvascular Permeability in ARDS

doi: 10.64898/2026.01.21.700786

Figure Lengend Snippet: Flow cytometric analysis of PMN distribution across lung compartments—blood (A) , endothelial-adherent (B) , interstitial (C) , and BAL (D) -24 hours after LPS inhalation with or without systemic ADAM17 inhibition (n = 4/13–14/7/7). (E) Quantification of CXCL2/3 in BAL fluid three hours after LPS inhalation by ELISA (n = 4/12/7/7). (F) Quantification of JAM-A MFI on pulmonary endothelial cells 24 hours after LPS inhalation (n = 4/14/7/7). (G) Quantification of VE-cadherin MFI in lung tissue using LasX (n = 4 mice per group; 10 measurements per image). (H–I) Photometric quantification of Evans blue in plasma (H) and lung tissue (I) six hours after LPS inhalation (n = 4/11/7/6–7). The data shown for ADAM17 fl/fl Tie2-Cre - controls were previously presented in the following panels: in , in , in , and in (to minimize animal numbers in accordance with the 3R principle). Data are presented as mean ± SD; Statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA.

Techniques: Inhibition, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

Levels of ADAM17 species in AD brain samples. Extracts from prefrontal cortex from non-dementia controls (NDC, n = 13) and AD ( n = 16) were analyzed by SDS-PAGE/electrophoresis and western blot. Each individual ADAM17 immunoreactive band was quantified and normalized using GAPDH. A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody. B Quantification of immunoreactive bands assigned to immature (iADAM17) and C mature (mADAM17) species with respect to GAPDH. D Values for the of mADAM17/iADAM17 ratio determined for each sample. The graphs represent mean ± SEM

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: Levels of ADAM17 species in AD brain samples. Extracts from prefrontal cortex from non-dementia controls (NDC, n = 13) and AD ( n = 16) were analyzed by SDS-PAGE/electrophoresis and western blot. Each individual ADAM17 immunoreactive band was quantified and normalized using GAPDH. A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody. B Quantification of immunoreactive bands assigned to immature (iADAM17) and C mature (mADAM17) species with respect to GAPDH. D Values for the of mADAM17/iADAM17 ratio determined for each sample. The graphs represent mean ± SEM

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques: SDS Page, Electrophoresis, Western Blot, Incubation

Aβ affects ADAM10 levels, but not ADAM17, in SH-SY5Y-differentiated neurons. SH-SY5Y cell cultures were differentiated to neurons with 10 µM retinoic acid treatment and then treated with 3 µM of Aβ42 for 48 h. A Representative western blot of control ( C ) and Aβ-treated (Aβ42) cell samples that was resolved with the anti C-terminal ADAM10 antibody (ab124695, Abcam). B Densitometric quantification of immunoreactive bands of iADAM10 and C mADAM10 with respect to GAPDH. Values represent the percentage with respect to control. D Values of the ratio between mature vs. immature species of ADAM10 (mADAM10/iADAM10). E Representative western blot of ADAM17 species resolved with anti-ectodomain region ADAM17 antibody (AF9301, R&D Systems) and the respective quantifications of F iADAM17 and G mADAM17 immunoreactive bands normalized to the ubiquitous protein GAPDH. H Result of the ratio of mADAM17/iADAM17. The graphs represent mean ± SEM of n = 12 samples of 3 independent experiments. Significant P < 0.05 values assayed by t-test are indicated

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: Aβ affects ADAM10 levels, but not ADAM17, in SH-SY5Y-differentiated neurons. SH-SY5Y cell cultures were differentiated to neurons with 10 µM retinoic acid treatment and then treated with 3 µM of Aβ42 for 48 h. A Representative western blot of control ( C ) and Aβ-treated (Aβ42) cell samples that was resolved with the anti C-terminal ADAM10 antibody (ab124695, Abcam). B Densitometric quantification of immunoreactive bands of iADAM10 and C mADAM10 with respect to GAPDH. Values represent the percentage with respect to control. D Values of the ratio between mature vs. immature species of ADAM10 (mADAM10/iADAM10). E Representative western blot of ADAM17 species resolved with anti-ectodomain region ADAM17 antibody (AF9301, R&D Systems) and the respective quantifications of F iADAM17 and G mADAM17 immunoreactive bands normalized to the ubiquitous protein GAPDH. H Result of the ratio of mADAM17/iADAM17. The graphs represent mean ± SEM of n = 12 samples of 3 independent experiments. Significant P < 0.05 values assayed by t-test are indicated

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques: Western Blot, Control

ADAM10 and ADAM17 CSF levels are not altered with aging. Representative blots of CSF samples of non-AD control individuals with large age amplitude (the age of the subjects are shown on top) probed with ( A ) anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva) and ( B ) ADAM17 antibody towards the ectodomain region (AF9301, R&D Systems). Correlations between the age and the levels of ADAM10 and ADAM17 species ( C ) iADAM10, ( D ) mADAM10, ( E ) sADAM10, ( F ) iADAM17, ( G ) mADAM17 and ( H ) sADAM17 were assayed. All graphs include their Spearman coefficient (r) and the P value. None of the ADAM10 species nor ADAM17 correlate with age. * Refers to unspecific bands

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: ADAM10 and ADAM17 CSF levels are not altered with aging. Representative blots of CSF samples of non-AD control individuals with large age amplitude (the age of the subjects are shown on top) probed with ( A ) anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva) and ( B ) ADAM17 antibody towards the ectodomain region (AF9301, R&D Systems). Correlations between the age and the levels of ADAM10 and ADAM17 species ( C ) iADAM10, ( D ) mADAM10, ( E ) sADAM10, ( F ) iADAM17, ( G ) mADAM17 and ( H ) sADAM17 were assayed. All graphs include their Spearman coefficient (r) and the P value. None of the ADAM10 species nor ADAM17 correlate with age. * Refers to unspecific bands

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques: Control

Levels of ADAM10 and ADAM17 species in AD CSF samples. Analysis of CSF ADAM10 and ADAM17 in non-AD controls (NADC) and in AD patients. A Representative blot of CSF probed against anti-ADAM10 ectodomain antibody. Quantification of immunoreactive band values obtained from B iADAM10, C mADAM10 and D sADAM10. E Values of the ratio between mature vs immature species of ADAM10 (mADAM10/iADAM10). F Representative blot of CSF probed against ADAM17 and the quantifications of the immunoreactivity of the bands for G iADAM17, H mADAM17 and I sADAM17. J Result of the ratio mADAM10/iADAM10. The graphs represent mean ± SEM. Significant P < 0.05 values assayed by t-test are indicated. * Refers to unspecific bands

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: Levels of ADAM10 and ADAM17 species in AD CSF samples. Analysis of CSF ADAM10 and ADAM17 in non-AD controls (NADC) and in AD patients. A Representative blot of CSF probed against anti-ADAM10 ectodomain antibody. Quantification of immunoreactive band values obtained from B iADAM10, C mADAM10 and D sADAM10. E Values of the ratio between mature vs immature species of ADAM10 (mADAM10/iADAM10). F Representative blot of CSF probed against ADAM17 and the quantifications of the immunoreactivity of the bands for G iADAM17, H mADAM17 and I sADAM17. J Result of the ratio mADAM10/iADAM10. The graphs represent mean ± SEM. Significant P < 0.05 values assayed by t-test are indicated. * Refers to unspecific bands

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques:

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques: SDS Page, Electrophoresis, Western Blot, Incubation

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques: Western Blot, Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques: Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Article Snippet: A Representative western blot incubated with anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems) and anti-GAPDH antibody.

Techniques:

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Article Snippet: E Representative western blot of ADAM17 species resolved with anti-ectodomain region ADAM17 antibody (AF9301, R&D Systems) and the respective quantifications of F iADAM17 and G mADAM17 immunoreactive bands normalized to the ubiquitous protein GAPDH.

Techniques: SDS Page, Electrophoresis, Western Blot, Incubation

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Techniques: Western Blot, Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Techniques: Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Techniques:

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Article Snippet: Following electrophoresis, proteins were transferred to 0.2 μm nitrocellulose membranes (Bio-Rad Laboratories GmbH, Munich, Germany), blocked with commercial blocking buffer (Cat. No 927–70001, LI-COR Biosciences, Lincoln, NE, USA), and probed with the following primary antibodies: rabbit anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva Systems Biology, San Diego, CA, USA); rabbit anti-ADAM10 monoclonal antibody to the C-terminal region (ab124695, Abcam, Cambridge, UK); and goat anti-ADAM17 polyclonal antibody towards the ectodomain region (AF9301, R&D Systems, Minneapolis, MN, USA).

Techniques: SDS Page, Electrophoresis, Western Blot, Incubation

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Techniques: Western Blot, Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Techniques: Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Techniques:

The proliferation of tracheal epithelial cells induced by GM‐CSF was inhibited by lentivirus‐mediated ADAM17 RNAi.

Journal: Canadian Respiratory Journal

Article Title: TAPI‐1 Combined With Silicone Stents Alleviated Severe Traumatic Tracheal Stenosis via the ADAM17/TGF‐β1 Pathway

doi: 10.1155/carj/9485331

Figure Lengend Snippet: The proliferation of tracheal epithelial cells induced by GM‐CSF was inhibited by lentivirus‐mediated ADAM17 RNAi.

Article Snippet: After blocking with 5% skim milk at room temperature for 1 h, the membranes were incubated with the following primary antibodies at 4°C for 12 h: ADAM17 (29948‐1‐AP; Proteintech, USA), TGF‐β1 (21898‐1‐AP; Proteintech, USA), fibronectin (15613‐1‐AP; Proteintech, USA), and β‐actin antibody (D110001‐0100; Sangon, Shanghai, China), all at a dilution of 1:1000.

Techniques:

Review

Structured Review

Images

1) Product Images from "Endothelial ADAM17 Promotes Neutrophil Migration and Pulmonary Microvascular Permeability in ARDS"

Similar Products

Image Search Results